Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida, or Friedreich’s ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head, or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet, or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.
The SCI pipeline drugs market research report provides comprehensive information on the therapeutics under development for SCI, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for SCI and features dormant and discontinued projects.
SCI Pipeline Drugs Market Segmentation by Targets
Some of the targets of the SCI pipeline drugs market are Receptor Type Tyrosine Protein Phosphatase S, Reticulon 4, Apoptosis Associated Speck Like Protein Containing A CARD, Free Radical, Glutamate Ionotropic Receptor AMPA Type Subunit, and Phospholipase A2.
SCI Pipeline Drugs Market Analysis, by Targets
For more SCI pipeline drugs market target insights, download a free report sample
SCI Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the SCI pipeline drugs market are Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Reticulon 4 Inhibitor, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, Free Radical Scavenger, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Phospholipase A2 Inhibitor.
SCI Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the SCI pipeline drugs market, download a free report sample
SCI Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the SCI pipeline drugs market are intrathecal, intravenous, oral, parenteral, subcutaneous, and intracerebral.
SCI Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the SCI pipeline drugs market, download a free report sample
SCI Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the SCI pipeline drugs market are Cell Therapy, Small Molecule, Synthetic Peptide, Gene Therapy, Monoclonal Antibody, and Biologic.
SCI Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the SCI pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the SCI pipeline drugs market are NervGen Pharma Corp, AXONIS Therapeutics Inc, Axoltis Pharma SAS, Novoron Bioscience Inc, RespireRx Pharmaceuticals Inc, and SanBio Co Ltd.
SCI Pipeline Drugs Market Analysis, by Companies
To know more about the SCI pipeline drugs market companies, download a free report sample
SCI Pipeline Drugs Market Report Overview
Key Targets | Receptor Type Tyrosine Protein Phosphatase S, Reticulon 4, Apoptosis Associated Speck Like Protein Containing A CARD, Free Radical, Glutamate Ionotropic Receptor AMPA Type Subunit, and Phospholipase A2 |
Key Mechanism of Actions | Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Reticulon 4 Inhibitor, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, Free Radical Scavenger, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Phospholipase A2 Inhibitor |
Key Routes of Administration | Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, and Intracerebral |
Key Molecule Types | Cell Therapy, Small Molecule, Synthetic Peptide, Gene Therapy, Monoclonal Antibody, and Biologic |
Key Companies | NervGen Pharma Corp, AXONIS Therapeutics Inc, Axoltis Pharma SAS, Novoron Bioscience Inc, RespireRx Pharmaceuticals Inc, and SanBio Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of SCI.
- Reviews of pipeline therapeutics for SCI by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews key companies involved in SCI therapeutics and enlist all their major and minor projects.
- Evaluation of SCI therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for SCI.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for SCI.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the SCI pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
AbbVie Inc
AlaMab Therapeutics Inc
Angion Biomedica Corp
Aposcience AG
Asha Therapeutics LLC
AstraZeneca Plc
Athersys Inc
Axoltis Pharma SAS
Axoneural Therapeutics Inc
AXONIS Therapeutics Inc
BioAxone BioSciences Inc
Cellatoz Therapeutics Inc
CellCure
CSL Ltd
Daewoong Pharmaceutical Co Ltd
EUSOL Biotech Co Ltd
GABA Therapeutics Inc
Gene Therapy Research Institution Co Ltd
Genervon Biopharmaceuticals LLC
GNT Pharma Co Ltd
Helixmith Co Ltd
Hemostemix Inc
Hibernaid Inc
Histocell SL
Hope Biosciences LLC
Hopstem Biotechnology LLC
iCELL Biotechnology Co Ltd
Jazz Pharmaceuticals Plc
Kidswell Bio Corp
Kringle Pharma Inc
Lineage Cell Therapeutics Inc
Locate Bio Ltd
Mapreg SAS
Mitsubishi Tanabe Pharma Corp
NervGen Pharma Corp
NeuExcell Therapeutics Inc
Neuroplast BV
New World Laboratories Inc
Novago Therapeutics AG
Novartis AG
Novoron Bioscience Inc
NuNerve Pty Ltd
Oligogen Inc
Palisade Bio, Inc
PharmatrophiX Inc
Q Therapeutics Inc
Q32 Bio Inc
Radikal Therapeutics Inc
RE-Stem Biotech Co Ltd
ReNetX Bio
RespireRx Pharmaceuticals Inc
Rudacure Co Ltd
S.Biomedics Co Ltd
SanBio Co Ltd
Shanghai Angecon Biotechnology Co Ltd
Stand Up Therapeutics Co Ltd
StemCyte Inc
Stemedica Cell Technologies Inc
Stemmatters Biotecnologia e Medicina Regenerativa SA
Sumitomo Pharma Co Ltd
TechnoPhage SA
Truvitech LLC
Tumorend LLC
VersaPeutics Inc
ZyVersa Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the SCI pipeline drugs market?
Some of the key targets of the SCI pipeline drugs market are the Receptor Type Tyrosine Protein Phosphatase S, Reticulon 4, Apoptosis Associated Speck Like Protein Containing A CARD, Free Radical, Glutamate Ionotropic Receptor AMPA Type Subunit, and Phospholipase A2.
-
What are the key mechanisms of action in the SCI pipeline drugs market?
Some of the key mechanisms of action in the SCI pipeline drugs market are Receptor Type Tyrosine Protein Phosphatase S Inhibitor, Reticulon 4 Inhibitor, Apoptosis Associated Speck Like Protein Containing A CARD Inhibitor, Free Radical Scavenger, Glutamate Ionotropic Receptor AMPA Type Subunit Agonist, and Phospholipase A2 Inhibitor.
-
What are the key routes of administration in the SCI pipeline drugs market?
The key routes of administration in the SCI pipeline drugs market are intrathecal, intravenous, oral, parenteral, subcutaneous, and intracerebral.
-
What are the key molecule types in the SCI pipeline drugs market?
The molecule types in the SCI pipeline drugs market are Cell Therapy, Small molecules, Synthetic Peptide, Gene Therapy, Monoclonal Antibody, and Biologic.
-
Which are the leading companies in the SCI pipeline drugs market?
Some of the leading companies in the SCI pipeline drugs market are NervGen Pharma Corp, AXONIS Therapeutics Inc, Axoltis Pharma SAS, Novoron Bioscience Inc, RespireRx Pharmaceuticals Inc, and SanBio Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.